Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer Cells
Patients with advanced prostate cancer (PCa) invariably develop resistance to anti-androgen therapy and taxane-based chemotherapy. Glucocorticoid receptor (GR) has been implicated in PCa therapy resistance; however, the mechanisms underlying GR-mediated chemoresistance remain unclear. Lens epitheliu...
Main Authors: | Evelyn S. Sanchez-Hernandez, Pedro T. Ochoa, Tise Suzuki, Greisha L. Ortiz-Hernandez, Juli J. Unternaehrer, Hossam R. Alkashgari, Carlos J. Diaz Osterman, Shannalee R. Martinez, Zhong Chen, Isaac Kremsky, Charles Wang, Carlos A. Casiano |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-08-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/12/16/2046 |
Similar Items
-
The LEDGF/p75 Integrase Binding Domain Interactome Contributes to the Survival, Clonogenicity, and Tumorsphere Formation of Docetaxel-Resistant Prostate Cancer Cells
by: Greisha L. Ortiz-Hernandez, et al.
Published: (2021-10-01) -
Glucocorticoid Receptor and β-Catenin Interact in Prostate Cancer Cells and Their Co-Inhibition Attenuates Tumorsphere Formation, Stemness, and Docetaxel Resistance
by: Shannalee R. Martinez, et al.
Published: (2023-04-01) -
The selenium-containing drug ebselen potently disrupts LEDGF/p75-HIV-1 integrase interaction by targeting LEDGF/p75
by: Da-Wei Zhang, et al.
Published: (2020-01-01) -
LEDGF/p75 Is Required for an Efficient DNA Damage Response
by: Victoria Liedtke, et al.
Published: (2021-05-01) -
LEDGIN-mediated Inhibition of Integrase–LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV
by: Lenard S. Vranckx, et al.
Published: (2016-06-01)